CommercialCoverageMedium impact
08.00.74ac, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Aug 3, 2026
We identified it
Jun 19, 2026
Summary
Medical necessity criteria for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors will be updated. This affects coverage requirements for eye injections used to treat conditions like macular degeneration and diabetic retinopathy.
Action Required
By August 3, 2026: Billing team must review and implement updated medical necessity criteria for intravitreal VEGF injections. Update documentation requirements in EMR templates to ensure compliance with new criteria. Providers must ensure proper medical necessity documentation is present before billing. Claims may be denied if new medical necessity criteria are not met.